A U.S. government scientist who oversees the team responsible for collecting data on COVID-19 and RSV hospitalizations used ...

Moderna's shares fell 2.5% before the bell on Friday, on concerns whether a new CDC advisory panel would back the use of the ...

The panel meeting for Moderna's RSV shot, scheduled for later this month, will be the "first time for investors to see the ...

The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the ...

A Centers for Disease Control and Prevention official who led the agency's network to study hospitalization trends from ...

The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus vaccine to a ...

Fiona Havers, who oversaw CDC respiratory virus data, told colleagues she no longer had confidence the data would be used ...

The 17 members of the CDC's vaccine advisory committee, who were ousted last week, argued their abrupt dismissal has "left ...

Key Takeaways A top U.S. government scientist has resigned amid concerns about vaccine policyExperts agree that recent ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to ...

(Reuters) -Moderna's shares fell 2.3% on Friday on concerns about whether a new CDC advisory panel would back the use of the company's respiratory syncytial virus vaccine in a broader age group.